API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2008
(Rs. In Lacs)
Particulars Quarter ended Quarter ended Half Year Ended
30th June 2008 30th June 2007 31st Mar 2008
1.
(Gross) Sales / Income from operations 11,162 7,859 33,585
2. Less : Excise Duty & Sales Tax 991 798 2,512
3. (Net) Sales / Income from operations 10,171 7,061 31,073
4. Other Income 4 61 184
5. Total Income 10,175 7,122 31,257
6. Expenditure
(a)
(Increase) / Decrease in stock in trade
161 (506) (924)
(b) Consumption of raw materials. 5,962 4,918 18,259
(c) Purchase of Traded Goods 850 454 3,892
(d) Employees cost 256 238 980
(e) Depreciation 257 224 963
(f) Other expenditure 1,305 1,105 5,119
7. Total Expenditure 8,719 6,433 28,289
8. Interest 560 164 1,184
9. Exceptional Items - - -
10. Profit Before Tax (PBT) 824 525 1,783
11. Provision for Tax & FBT 110 60 246
12. Profit After Tax (PAT) 714 465 1,537
13. Provision for Deferred Tax 63 57 230
14. Profit After Deferred Tax 651 408 1,307
15.
Paid-up Equity Share Capital of Rs.10/- each.
1,171 1,171 1,171
16.
Reserves & Surplus (excluding revaluation reserves)
- - 9,734
17. Basic E P S (in Rs.) 5.56 3.48 11.17
18. Aggregate of Non Promoter Shareholding
19. Number of Shares 5932388 5516110 6045866
20. Percentage of Total Shareholding 50.67 47.11 51.64

Notes :

1.There were no pending complaints at the beginning of the Quarter. During the quarter three complaintswere received and redressed. There were no complaints pending at the end of the quarter.


2.The above results for the Quarter ended 30-6-2008 include foreign exchange fluctuation loss of Rs.208 lakhs on account of borrowings.


3.Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 . 'Segment Reporting' is not attracted.


4.The figures of the previous periods have been regrouped and rearranged wherever necessary.


5.The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 28th July, 2008.

For and on behalf of the Board

FOR AARTI DRUGS LIMITED

Sd/-

Place : Mumbai Harshit M Savla

Date : 30th Oct, 2009 (Jt. Managing Director)

 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech